ClinicalTrials.gg
Not yet recruitingNCT07514624CRMF-MFRUpdated Apr 7, 2026

CRIC Combined With MFT for MFR in Patients With Incomplete Revascularization of CAD

An interventional study of CRIC and MFT in Coronary Disease, sponsored by Henan Institute of Cardiovascular Epidemiology. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Henan Institute of Cardiovascular Epidemiology · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of this study is to demonstrate whether the combination of chronic remote ischemic conditioning and mindfulness therapy can improve myocardial flow reserve in patients with incomplete revascularization of coronary artery disease.

02

Conditions studied

  • Coronary Disease

Browse trials for

Keywords

  • CAD
  • MFR
  • RIPC
03

In context

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

This study's planned enrollment of 480 is above the median of 160 across 780 interventional studies indexed under Coronary Disease.

Browse Coronary Disease studies →

Lead sponsor

Henan Institute of Cardiovascular Epidemiology is the lead sponsor of 31 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old
  • Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least one vessel with a reference diameter of 3.0mm had stenosis greater than 90%, and quantitative flow ratio (QFR) \< 0.80)
  • Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.);

Exclusion criteria

Exclusion Criteria:

    • Age \< 18 years old

      • Heart failure patients with class IV, or (LVEF) \< 30%
      • \<15 mL/min (or \< 15 mL/min/1.73m²), or requires dialysis
      • Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.
      • Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular rates, supraventricular tachycardia to drugs)
      • Poorly controlled hypertension (SBP > 180 mm Hg or DBP > 110 mm Hg)
      • Active liver disease or persistent or AST elevation ≥ 3 times the
      • Unexplained CK > 5 times the upper limit of normal, or elevated CK due to known muscle disease
      • Planned or anticipated cardiac surgery or revascularization before randomization
      • History of active (surgery, radiation therapy, and/or systemic therapy within the past 3 years)
      • Diagnosed or suspected upper extremity vascular malformations, aneurysms, arteriovenous fistulas, or thrombosis
      • Hearing impairment, unable to undergo mindfulness therapy
      • Currently participating in another drug or device study, or within 30 days of completing another drug or device study or receiving another drug
      • Any life-threatening comorbid conditions expected to result in death within the next year (excluding cardiovascular diseases)
      • Alcoholism, substance abuse history; and unwilling or unable to stop alcohol or substance abuse during the study
      • History of major organ transplant (e.g., lung, liver, heart, bone marrow, kidney)
      • Investigator's judgment of known major active and uncontrolled disease, or any medical, physical, or surgical conditions (e.g., infection, significant blood, kidney, metabolic, gastrointestinal, or endocrine dysfunction) that may interfere with participation in the clinical study
      • As known to the investigator, the subject is unlikely to complete follow-up for more than 1 year or is expected to be unable to comply with the study requirements or understand the study's objectives and potential risks.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    CRIC+MFT

    CIRC: Using a semi-automated machine, the pressure is increased according to the patient's own blood pressure level (20-40mmHg) when the cuff is pressed, and the pressure is compressed for 6 minutes per cycle, and the rest is 4 minutes per cycle. Perform twice daily, with 4 cycles per session. MFT: Participants receive guided mindfulness audio sessions twice daily for \~30 minutes each throughout the perioperative period. Content includes standardized mindfulness practices (e.g., focused attention, body awareness, nonjudgmental observation) designed to reduce anxiety and improve sleep quality.

    Device: CRIC · Behavioral: MFT

  • Sham comparator
    Control (neither CRIC nor MFT).

    Sham CRIC: The pressure was 60mmHg when the cuff was pressurized, and the other modes were the same as those of the CIRC group. Perform twice daily, with 4 cycles per session. Sham MFT: Health Education + Relaxation (HER):A time- and attention-matched audio program (twice daily, 30 minutes) delivering perioperative recovery and sleep-hygiene education with passive relaxation(music or simple muscle loosening), excludingmindfulness-specific techniques (no present-moment/ nonjudgmental awareness training, no breath-focused meditation, no open monitoring).

    Device: sham CIRC · Behavioral: sham MFT

  • Sham comparator
    CRIC+sham MFT

    CIRC: Using a semi-automated machine, the pressure is increased according to the patient's own blood pressure level (20-40mmHg) when the cuff is pressed, and the pressure is compressed for 6 minutes per cycle, and the rest is 4 minutes per cycle. Perform twice daily, with 4 cycles per session. Sham MFT: Health Education + Relaxation (HER):A time- and attention-matched audio program (twice daily, 30 minutes) delivering perioperative recovery and sleep-hygiene education with passive relaxation(music or simple muscle loosening), excludingmindfulness-specific techniques (no present-moment/ nonjudgmental awareness training, no breath-focused meditation, no open monitoring).

    Device: CRIC · Behavioral: sham MFT

  • Sham comparator
    sham CRIC+MFT

    Sham CRIC: The pressure was 60mmHg when the cuff was pressurized, and the other modes were the same as those of the CIRC group. Perform twice daily, with 4 cycles per session. MFT: Participants receive guided mindfulness audio sessions twice daily for \~30 minutes each throughout the perioperative period. Content includes standardized mindfulness practices (e.g., focused attention, body awareness, nonjudgmental observation) designed to reduce anxiety and improve sleep quality.

    Behavioral: MFT · Device: sham CIRC

Interventions

  • DeviceCRIC

    chronic remote ischemic conditioning Using a semi-automated machine, the pressure is increased according to the patient's own blood pressure level (20-40mmHg) when the cuff is pressed, and the pressure is squeezed for 6 minutes per cycle and the rest is 4 minutes, for a total of 4 cycles per cycle.

  • BehavioralMFT

    Participants receive guided mindfulness audio sessions twice daily for \~30 minutes each throughout the perioperative period. Content includes standardized mindfulness practices (e.g., focused attention, body awareness, nonjudgmental observation) designed to reduce anxiety and improve sleep quality.

  • Devicesham CIRC

    The pressure was 60mmHg when the cuff was pressurized, and the other modes were the same as in the CIRC group.

  • Behavioralsham MFT

    A time- and attention-matched audio program (twice daily, 30 minutes) delivering perioperative recovery and sleep-hygiene education with passive relaxation (music or simple muscle loosening), excluding mindfulness-specific techniques (no present-moment/ nonjudgmental awareness training, no breath-focused meditation, no open monitoring).

06

What researchers measure

Primary outcomes

  1. Change in Myocardial Flow Reserve (MFR)

    Change in myocardial flow reserve (MFR) assessed by CT myocardial perfusion imaging from baseline to 6 months after randomization.

    Time frame: 6 months

Secondary outcomes

  1. Incidence of MACE

    Clinical events were defined as: cardiac death, nonfatal myocardial infarction, hospitalization for new heart failure,hospitalization for angina pectoris

    Time frame: 3,6,9,12,24months

  2. Incidence of Cardiac Death

    Death is considered cardiac unless there is clear evidence of non-cardiac death

    Time frame: 3,6,9,12,24months

  3. Incidence of Non-fatal Myocardial Infarction

    Includes STEMI and NSTEMI with elevated serum troponin on the basis of patient symptoms or ECG changes

    Time frame: 3,6,9,12,24months

  4. Incidence of hospitalisation for new-onset heart failure

    New onset of heart failure-related symptoms with elevated serum BNP or NT-ProBNP

    Time frame: 3,6,9,12,24months

  5. Incidence of hospitalised for angina pectoris

    Hospitalisation for angina pectoris symptoms of all causes, with a discharge diagnosis of angina pectoris

    Time frame: 3,6,9,12,24months

  6. Incidence of unplanned revascularisation

    Unplanned revascularisation

    Time frame: 3,6,9,12,24months

  7. Incidence of all cause death

    Death from any cause

    Time frame: 3,6,9,12,24months

  8. Incidence of total length of hospitalization due to coronary heart disease

    Refers to the number of days when all hospitalizations for all causes of coronary heart disease are stacked together

    Time frame: 3,6,9,12,24months

  9. Medical expenses due to coronary heart disease

    Refers to medical expenses incurred as a result of coronary heart disease

    Time frame: 3,6,9,12,24months

  10. Degree of improvement in angina symptoms

    The degree of improvement in angina symptoms will be assessed using the Seattle Angina Questionnaire (SAQ), a 19-item self-administered questionnaire that evaluates five domains of health status in patients with coronary artery disease: physical limitation (9 items), angina stability (1 item), angina frequency (2 items), treatment satisfaction (4 items), and disease perception (3 items). Each domain score ranges from 0 to 100, with higher scores indicating better function (e.g., less physical limitation, less frequent angina, and better quality of life). A summary score, averaging the physical limitation, angina frequency, and quality of life domains, also ranges from 0 to 100. Improvement will be measured as the change in SAQ domain scores and summary score from baseline to follow-up time points, where an increase of 10 points or more in any domain or the summary score is considered clinically significant.

    Time frame: 3,6,9,12,24months

  11. Change in anxiety scores

    Changes in anxiety scores will be assessed using the Zung Self-Rating Anxiety Scale (SAS), a 20-item self-report questionnaire that measures anxiety symptoms across cognitive, autonomic, motor, and central nervous system domains. Each item is rated on a 4-point Likert scale (1 = "none or a little of the time" to 4 = "most or all of the time"), yielding a raw total score ranging from 20 to 80, with higher scores indicating greater anxiety severity. Raw scores can be converted to an index score by multiplying by 1.25 (range: 25 to 100). The change in anxiety scores will be calculated as the difference in raw SAS scores from baseline to follow-up time points. For reference, raw scores are typically interpreted as: \<36 (normal), 36-47 (mild anxiety), 48-59 (moderate anxiety), and ≥60 (severe anxiety).

    Time frame: 3,6,9,12,24months

  12. Change in depression scores

    Changes in depression scores will be assessed using the Zung Self-Rating Depression Scale (SDS), a 20-item self- report questionnaire that measures depressive symptoms across affective, psychological, and somatic domains. Each item is rated on a 4-point Likert scale (1 = "none or a little of the time" to 4 = "most or all of the time"), yielding a raw total score ranging from 20 to 80, with higher scores indicating greater depression severity. Raw scores can be converted to an index score by multiplying by 1.25 (range: 25 to 100). The change in depression scores will be calculated as the difference in raw SDS scores from baseline to follow-up time points. For reference, raw scores are typically interpreted as: \<40 (normal), 40-47 (mild depression), 48-55 (moderate depression), and ≥56 (severe depression).

    Time frame: 3,6,9,12,24months

  13. Changes in sleep quality

    Changes in sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a 19-item self-report questionnaire that evaluates sleep quality over the past month across seven components: subjective sleep quality (1 item), sleep latency (2 items), sleep duration (1 item), habitual sleep efficiency (3 items), sleep disturbances (9 items), use of sleeping medication (1 item), and daytime dysfunction (2 items). Each component is scored from 0 to 3, with higher scores indicating greater dysfunction. The global PSQI score is the sum of the seven omponents and ranges from 0 to 21, with higher scores indicating poorer sleep quality. Changes in sleep quality will be calculated as the difference in global PSQI scores from baseline to follow-up time points. For reference, a global score \>5 is indicative of poor sleep quality.

    Time frame: 3,6,9,12,24months

  14. Mean Nocturnal Systolic Blood Pressure

    Measurement using smart wearable devices

    Time frame: 3,6,9,12,24months

  15. Average sleep duration (hours per night)

    Average total sleep time per night, measured using a smart wearable device. Data will be reported as mean (±SD) hours per night.

    Time frame: 3,6,9,12,24months

  16. average heart rate

    Measurement using smart wearable devices

    Time frame: 3,6,9,12,24months

  17. Sleep quality (measured by sleep efficiency, %)

    Sleep efficiency (%) assessed using a smart wearable device, defined as the ratio of total sleep time to time in bed. Data will be reported as mean (±SD) percentage. Higher values indicate better sleep quality.

    Time frame: 3,6,9,12,24months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Sep 2028, 28 months later.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 28 months is close to that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Apr 7, 2026
StartEst.
May 1, 2026
Primary completionEst.
Sep 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07514624
Lead sponsor
Henan Institute of Cardiovascular Epidemiology
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Apr 7, 2026

Study contacts

Quan Guo
Contact
xinyiguoquan@163.com
15670510031
Muwei LI
study chair · Fuwai Central China of Cardiovascular Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion